明德生物(002932.SZ):目前市值嚴重低估,實控人堅定看好公司未來的長期發展,短期內也未有減持計劃
格隆匯8月28日丨有投資者嚮明德生物(002932.SZ)提問,“根據最新規定,公司是不是股價破淨,大股東實際控制人都不能減持了?”
明德生物回覆稱,根據8月27日《證監會進一步規範股份減持行為》的通知,公司目前市值低於公司披露的最新一期歸屬於母公司股東的淨資產(65.87億元),上個交易日收盤價低於披露的最新一期每股淨資產(28.32元),因此控股股東、實際控制人不得通過二級市場減持本公司股份。公司目前市值嚴重低估,實際控制人堅定看好公司未來的長期發展,短期內也未有減持計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.